When the Department of Defense announced its contract awards for Aug. 6, the total funds handed out added up to $518.8 million -- but one single company walked away with more than half the funds on offer: Raytheon (NYSE: RTN ) .
Raytheon claimed its loot in the form of two contracts to perform work for the U.S. Missile Defense Agency, namely:
$218.5 million: exercising an option under a sole-source, cost-plus-incentive-fee contract to fund the purchase of materials, and integrate same into the manufacture of "up to" 29 All Up Rounds SM-3 Block IB missiles. SM-3IB is a new version of Raytheon's venerable Standard surface-to-air missile, which aims to enhance the original's effectiveness with enhanced, two-color infrared target seeking, and the use of short bursts of precision propulsion to steer the missile toward incoming targets. Raytheon's SM-3IBs are scheduled to begin deployment in 2015. The current contract, now worth $398 million in total, is expected to run through Sept. 30, 2016. $49.9 million: exercising an option under a different sole-source cost-plus-incentive-fee contract to manufacture four All Up Rounds SM-3 Block IB missiles. These missiles are deliverable on or before Sept. 30, 2015.Top Computer Hardware Companies To Buy Right Now: Acorda Therapeutics Inc.(ACOR)
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS with walking disability under the Fampyra name internationally. Its lead research and development programs include three biologic therapeutic approaches for restoring neurologic and cardiac function, which comprise Neuregulin Program for developing Glial Growth Factor 2, a molecule in the Phase I clinical trial for the treatment of heart failure; Remyelina ting Antibodies Program for developing rHIgM22, an antibody in the preclinical stage for treating MS; and Chondroitinase Program, a research stage program focused on developing chontroitinase as a therapeutic to break down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. In addition, the company has in-licensed a clinical-stage program, AC105, to develop an acute treatment for neurological trauma. It has collaboration agreement with Biogen Idec International GmbH to develop and commercialize products containing aminopyridines to the treatment of MS. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Hawthorne, New York.
Advisors' Opinion:- [By Ben Levisohn]
Acorda Therapeutics (ACOR) has dropped today after announcing the results of a clinical trial.
Getty ImagesFrom Accorda’s press release:
Acorda Therapeutics, Inc. today announced data from a Phase 2 proof-of-concept study of dalfampridine extended release tablets, 10 mg (dalfampridine-ER) in people with post-stroke deficits. In the study, treatment with dalfampridine-ER was well-tolerated and improved walking, as measured by the Timed 25-Foot Walk test (T25FW).
RBC Capital Markets’ Michael Yee and team put the news in context:
In the short-term, ACOR’s scripts look a bit mediocre tracking a tad shy of Q3 consensus, and overall new scripts are down too. Longerterm, we believe value creation will need to come from 1) expanding the label to a new indication in “post-stroke” pts which is going into Phase II/III and could theoretically double the commercial sales, 2) its re-myelinating antibody rHigM22 in Phase I might get attention because Biogen’s Phase II LINGO re-myelinating program could be very intriguing in H2:14. Risks are that a Paragraph IV should be expected in January 2014 around the corner and the “post-stroke” data is interesting but not as compelling versus the MS indication. Overall, however this will take some time to play out as the next post-stroke study doesn’t even begin until Q2:14 so data not until at least 2015+. That said, expectations are pretty low and we think the stock is pretty cheap at $1.1B EV or ~3x sales plus all potential upside from label expansion or pipeline.
MannKind (MNKD), meanwhile, has gained after asking the FDA to approve its inhaled diabetes drug Afrezza. The Associated Press has the details:
MannKind has no drugs on the market. It first filed for Food and Drug Administration approval of Afrezza in March 2009, and in early 2011 the FDA told the company to run more clinical studies. The agency wanted MannKind to use the stu
Top 5 Dow Dividend Stocks To Buy Right Now: Pharma-Bio Serv Inc (PBSV.PK)
Pharma-Bio Serv, Inc.( Pharma-Bio), incorporated on June 8, 2006, is a compliance and technology transfer services consulting firm with a laboratory testing facility, servicing the Puerto Rico, United States and Europe markets. The Company is engaged in providing technical compliance consulting service, and microbiological and chemical laboratory testing services primarily to the pharmaceutical, chemical, medical device and biotechnology industries. The Company�� operating segments include Puerto Rico technical compliance consulting, United States technical compliance consulting, Ireland technical compliance consulting and a Puerto Rico microbiological and chemical laboratory testing division (Lab). These segments provide services primarily to the pharmaceutical, chemical, medical device and biotechnology industries in their respective markets. As on April 30, 2012, the Company acquired 100% interest in its subsidiary, Pharma-IR.
The Company provides a broad range of compliance related consulting services. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It provides information technology consulting services and technical training/seminars. The Company offers services to its core industries already serviced as well as the cosmetic and food industries. The Company seeks opportunities in markets that could yield profitable margins using its professional consulting force and also provide services such as those performed by its microbiological testing laboratory facility, its information technology service division, Integratek, and its technical training division, Pharma Serv Academy.
The Company�� information technology services and consulting division based in Puerto Rico (Integratek) provides a variety of information technology services, such as Web pages and portals development, digital art design, intranets, extranets, software development including database integration, Window! s and Web applications development, software technical training and learning management systems, technology project management, and compliance consulting services, among others.
Advisors' Opinion:- [By The Specialist]
Normally when one of my stocks reports its earnings results after hours on a Friday, I cringe in anticipation of a bad report. Normally Friday after hours is a time slot reserved for companies who have disappointing results to deliver and wish to stay off radar. Naturally, when I got the alert on a Friday afternoon that Pharma-Bio Serv (PBSV.PK) had just reported its earnings results, I had one eye shut when opening the press release, fearing what would be inside.
Top 5 Dow Dividend Stocks To Buy Right Now: Molina Healthcare Inc (MOH)
Molina Healthcare, Inc., incorporated on July 24, 2002, provides medicaid-related solutions. The Company operates in two segments: Health Plans and Molina Medicaid Solutions. The Company's Health Plans segment consists of health plans in California, Florida, Michigan, New Mexico, Ohio, Texas, Utah, Washington, and Wisconsin, and includes the Company's direct delivery business. The Company's Molina Medicaid Solutions segment provides design, development, implementation, and business process outsourcing solutions to state governments for their Medicaid Management Information Systems (MMIS).As of December 31, 2012, Health Plans segment served approximately 1.8 million members eligible for Medicaid, Medicare, and other government-sponsored health care programs for low-income families and individuals. In June 2013, Molina Healthcare Inc announced that, through its wholly owned subsidiary, Molina Center LLC, it has successfully completed a sale and lease back transaction with the dedicated net lease group of Angelo, Gordon & Co (AG).
The health plans are operated by the Company's wholly owned subsidiaries in those states, each of which is licensed as a health maintenance organization (HMO). The Company's direct delivery business consists of 24 primary care clinics in California, Florida, New Mexico, and Washington, and the Company manages three county-owned primary care clinics under a contract with Fairfax County, Virginia. The Company's Health Plans segment derives its revenue principally in the form of premiums received under Medicaid contracts with the states in which the Company's health plans operate. All of the Company's health plans operate on a single managed care platform for claims processing (the QNXT 4.8 system). MMIS is a core tool used to support the administration of state Medicaid and other health care entitlement programs. Molina Medicaid Solutions holds MMIS contracts with the states of Idaho, Louisiana, Maine, New Jersey, and West Virginia, as well as a contract to provide d! rug rebate administration services for the Florida Medicaid program. The Company arranges health care services for its members through contracts with providers that include independent physicians and groups, hospitals, ancillary providers, and its own clinics. The Company's network of providers includes primary care physicians, specialists and hospitals. The Company contracts with both primary care physicians and specialists many of whom are organized into medical groups or independent practice associations (IPAs).
The Company develops specialized disease management programs that address the particular health care needs of its members. motherhood matters! sm is a comprehensive program designed to improve pregnancy outcomes and enhance member satisfaction. breathe with ease! is a multi-disciplinary disease management program that provides health education resources and case management services to assist physicians caring for asthmatic members between the ages of three and 15. Healthy Living with Diabetes is a diabetes disease management program. Heart Health Living is a cardiovascular disease management program for members who have suffered from congestive heart failure, angina, heart attack, or high blood pressure. The Company provides its members with information to guide them through various episodes of care. This information, which is available in several languages, is designed to educate parents on the use of primary care physicians, emergency rooms, and nurse call centers. The Company's pharmacy management programs focus on physician education regarding appropriate medication utilization and encouraging the use of generic medications. The Company's pharmacists and medical directors work with the Company's pharmacy benefits manager to maintain a formulary that promotes both improved patient care and generic drug use. The Company provides certain centralized medical and administrative services to its health plans pursuant to administrative services agreements, including medical affairs a! nd qualit! y management, health education, credentialing, management, financial, legal, information systems, and human resources services.
The Company competes with HP Enterprise Services, ACS, Computer Services Corporation, and CNSI.
Advisors' Opinion:- [By Susan J. Aluise]
Although big insurers may retreat in the near term, here are three healthcare stocks still poised to win big from the Affordable Care Act:
Healthcare Stocks: Molina Healthcare (MOH)Molina Healthcare (MOH) is an insurance payor focused on the Medicaid niche — it covers an estimates 2 million patients in 11 states.
Top 5 Dow Dividend Stocks To Buy Right Now: Harsco Corp (HSC)
Harsco Corporation, incorporated on February 28, 1956, is a diversified, multinational provider of industrial services and engineered products serving global industries. The Company operates in four segments: Harsco Metals & Minerals, Harsco Infrastructure, Harsco Rail and Harsco Industrial. The Company's principal lines of business include outsourced, on-site services to steel mills and other metals producers; resource recovery technologies for the re-use of industrial waste stream by-products; industrial abrasives and roofing granules; engineered scaffolding, concrete forming and shoring, and other access-related services, rentals and sales; railway track maintenance services and equipment; industrial grating products; air-cooled heat exchangers, and heat transfer products. In January 2014, the Company acquired Hammco Corp.
Harsco Metals & Minerals Segment
The Harsco Metals & Minerals Segment is a provider of on-site, outsourced services to the global metals industries. The Metals business provides its services and solutions on a long-term contract basis, supporting each stage of the metal-making process from initial raw material handling to post-production slag processing and metal recovery. The Minerals business extracts metallic content from stainless steel by-products and also specializes in the development of minerals technologies for commercial applications, including agriculture fertilizers. The Minerals business also produces industrial abrasives and roofing granules from power-plant utility coal slag at a number of locations throughout the United States. Harsco Minerals' BLACK BEAUTY abrasives are used for industrial surface preparation, such as rust removal and cleaning of bridges, ship hulls and various structures. Roofing granules are sold to residential roofing shingle manufacturers, primarily for the replacement roofing market. As of December 31, 2012, the Harsco Metals & Minerals Segment operated in approximately 35 countries. During the year ended December 3! 1, 2012, the Harsco Metals & Minerals Segment generated 46% of the Company�� total revenue.
Harsco Infrastructure Segment
The Harsco Infrastructure Segment is global organization for the rental and sale of engineered scaffolding, shoring, concrete forming and other access-related solutions for construction projects as well as industrial plant maintenance programs. The Segment operates from a network of branches throughout the world, including North America, Latin America, Europe, the Gulf Region of the Middle East, Africa and Asia-Pacific. The services include the provision of concrete shoring and forming systems; scaffolding for non-residential and infrastructure construction projects and industrial maintenance requirements, and a variety of other infrastructure services including project engineering and design, equipment erection and dismantling services, industrial insulation and painting services and equipment sales. During 2012, the Harsco Infrastructure Segment generated 31% of the Company�� total revenue.
Harsco Rail Segment
The Harsco Rail Segment is a global provider of equipment and services for the maintenance, repair and construction of railway track. The Segment's equipment and services support private and government-owned railroads and urban transit systems worldwide. The Segment's rail products are produced in three countries and products and services are provided worldwide. During 2012, the Harsco Rail Segment generated 11% of the Company�� total revenue.
Harsco Industrial Segment
Harsco Industrial Segment includes the Harsco Industrial IKG, Harsco Industrial Air-X-Changers and Harsco Industrial Patterson-Kelley businesses. Approximately 90% of this Segment's revenues originate in North America. Harsco Industrial IKG manufactures a line of industrial grating products at several plants in the United States and international plants located in Mexico and China. These products include a range of bar grating c! onfigurat! ions, which are used mainly in industrial flooring, as well as safety and security applications in the energy, paper, chemical, refining and processing industries.
Harsco Industrial Air-X-Changers is a supplier of custom-designed and manufactured air-cooled heat exchangers for the natural gas industry from plants in the United States and Australia. Harsco Industrial Air-X-Changers' heat exchangers are the primary apparatus used to condition natural gas during recovery, compression and transportation from underground reserves through the pipeline distribution channels. Harsco Industrial Patterson-Kelley is a manufacturer of heat transfer products, such as boilers and water heaters for commercial and institutional applications. During 2012, the Harsco Rail Segment generated 12% of the Company�� total revenue.
Advisors' Opinion:- [By Rich Smith]
Barry Malamud's long tour of duty as interim chief financial officer at Harsco (NYSE: HSC ) has come to an end.
On Monday, the Camp Hill, Pa.-based metals company announced that it is hiring F. Nicholas Grasberger as its new CFO, effective April 22. On that date, Malamud will resume his prior position as vice president and corporate controller for the company.
- [By Ben Levisohn]
Shares of Harsco (HSC) have gained today after BB&T Capital Markets upgraded its shares to Buy from Hold.
Analysts Robert Norfleet III and Basil Jones III explain the decision to raise their rating:
�We believe that the strategic transformation of HSC’s portfolio, as evidenced by the recently announced sale of its Infrastructure segment, as well as additional best practices and productivity enhancements (LEAN, etc.) should result in improved financial metrics, valuation, and, ultimately, a less complex business structure. While our non-consensus call is not primarily based on an expedited improvement in financial performance, it is a reflection of our confidence in the new management team and its ability to deliver value to shareholders through asset repositioning, improved ROICs and free cash flow generation. HSC remains a “turnaround story,” but we believe the market is underestimating out-year earnings growth, which will be driven by the Brand Energy JV, lower corporate expenses, improved margins in Metals & Minerals and the likelihood of an accretive acquisition.
Shares of Harsco have gained 4.7% to $26.43 today at 1:16 p.m., outpacing other construction & engineering companies. Dycom (DY) has advanced 0.5% to $30, KBR Inc. (KBR) has ticked up 0.1% to $33.03, Worthington Industries�(WOR) has risen 2.8% to $38.85�and Tutor Perini (TPC) has rallied 3.6% to $22.46.
No comments:
Post a Comment